Spot and Stop Common Errors With GLP-1 Agonists

February 2026

You’ll be challenged to avoid errors when dispensing GLP-1 agonists (semaglutide, etc.)...for weight loss, diabetes, and other conditions.

Product selection. Review the indications for each GLP-1 agonist and watch for mix-ups, as some meds are available in multiple products.

For example, Ozempic (semaglutide), Mounjaro (tirzepatide), and Victoza (liraglutide) are approved for diabetes. But Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) are for obesity.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Obesity & Weight Loss Be Ready to Dispense New ORAL Semaglutide for Weight Loss
Immunizations Listen for Questions About Childhood Immunizations
Fibromyalgia Know How Meds for Fibromyalgia Stack Up
COPD Prevent Mix-Ups With COPD Meds
Medication Errors Spot and Stop Common Errors With GLP-1 Agonists
Calculations Count On These Tips for Pharmacy Calculations
Menopause Stay Alert for Rumors About Menopausal Hormone Therapy
NatMed Spotlight Emphasize Lifestyle Approaches to Help Manage BP

Spot and Stop Common Errors With GLP-1 Agonists

Practical advice for a better career, with unlimited access to CE

Table of Contents